[Blood vessel multiply and significance of expression of Cox-2, VEGF in pterygium].
OBJECTIVE
To investigate the role of cyclooxygenases-2 (Cox-2) and vascular endothelial growth factor (VEGF) in the occurrence and development of human pterygium.


METHODS
The immunohistochemical elivision method was used to examine the expressions of Cox-2 and VEGF in 30 cases of pterygium and 15 cases with normal conjunctiva.


RESULTS
The positive rate of Cox-2 was 42.8% in resting stage, 84.6% in active stage, 90.0% in recurrent pterygium and 6.6% in normal conjunctiva. The positive rate of VEGF was 57.1% in resting stage, 69.2% in active stage, 100.0% in recurrent pterygium and 13.3% in the normal conjunctiva. There was significant difference in the expressions of Cox-2 and VEGF between the pterygium and normal conjunctiva (P < 0.05, P < 0.001).


CONCLUSIONS
There are high Cox-2 and VEGF expressions in pterygium, which suggests that there is abnormal blood vessel multiply in pterygium, and the Cox-2 and VEGF plays an important role in the incidence and development of pterygium. Specific Cox-2 and VEGF inhibitor become a new target for the therapy of pterygium. Specific Cox-2 and VEGF inhibitor become a new target for the therapy of pterygium.
Yan
Meirong
M
Department of Ophthalmology, 163 Hospital of PLA, Changsha 410003, China.
Li
Zhengxian
Z
Liu
Gengxun
G
Peng
Changfu
C
Zhou
Yiming
Y
Wang
Fang
F
D000328:Adult; D016022:Case-Control Studies; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000378:metabolism*; D011625:Pterygium / Q000378:metabolism* / Q000473:pathology*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism*
C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human